Navigation Links
SeqWright Expands into the Genetically-Targeted Therapy Field by Partnering with PharmaGenoma to Provide Next-Generation Hair Loss Treatment Genetic Testing
Date:4/28/2009

HOUSTON, April 28 /PRNewswire/ -- SeqWright Inc., a CLIA certified and GLP compliant provider of custom genomic and molecular biology services, announced today its entry into the genetically-targeted therapy field through its partnership with PharmaGenoma. SeqWright will be the exclusive genetic testing provider for PharmaGenoma's HairDX test which evaluates patient responsiveness to the common hair loss treatment, Finasteride.

Finasteride is a commonly prescribed medication for the treatment of Androgenic Alopecia (AGA) or common hair loss. The treatment works by blocking the production of dihydrotesterone (DHT), which is responsible for the loss of hair. However, due to potential Finasteride side effects, along with variations in responsiveness, many patients are reluctant to begin or continue treatment. In order to overcome this obstacle, HairDX developed a genetic test for Finasteride response which will allow patients to determine if treatment benefits outweigh potential side effects prior to beginning a Finasteride regimen.

"The state of the art research facility at SeqWright was essential to achieving our goals of high quality genetic analysis combined with a turn-around time useful for clinicians," said PharmaGenoma, CEO Andy Goren.

About SeqWright

Based in Houston, TX, SeqWright Incorporated is recognized as an international leader in the field of contract genomic services, inclucing next generation sequencing. For over fifteen years, SeqWright has provided state-of-the-art Molecular Biology and Genomic services, from small projects up to full clinical trials. SeqWright was recently awarded a license by the state of California to operate as a clinical laboratory. This license, along with its CLIA certification, allows SeqWright to handle clinical samples from the vast majority of the United States. For additional information about SeqWright and its services, please visit www.seqwright.com.

About PharmaGenoma, Inc.

PharmaGenoma, Inc. Based in Irvine, CA, USA is a molecular dermatology research and development company. PharmaGenoma and its subsidary HairDX market the first genetic test for male and female hair loss. The company is dedicated to the research and development of new prescription based therapies tailored to an individual's genetic make up. PharmaGenoma uses only CLIA certified laboratories (Clinical Laboratory Improvement Amendments) to perform the genetic analysis. The HairDX test collection kit is listed with Japan's Pharmaceuticals and Medical Devices Agency (PMDA) and the United States Food and Drug Administration (FDA) as a Class I medical device.


'/>"/>
SOURCE SeqWright Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. SeqWright to Invest in LaserGens Novel Lightning Terminators(TM)
2. California Grants SeqWright License to Operate as a Clinical Laboratory
3. SeqWright Expands Next Generation Lineup with the Addition of 454s GS FLX(TM) System
4. SeqWright Unveils ABI SOLiD(TM) Next Generation Genetic Analysis System
5. Xspray Expands to Meet Pharmas Interest in its Ground-Breaking Particle Production Technology
6. Microtest Labs Expands Clean Room, Contamination Testing Services
7. Health Strategies Group Expands Focus of Pharma Sales Force Effectiveness Service Under New Vision and Name
8. Proteolix Announces New Appointment in Finance and Expands Clinical and Regulatory Leadership Team
9. Prolifiq Further Expands Into Medical Markets With New Hire Maureen A. Shaffer
10. SAFC Biosciences(R) Expands Media Capability for Chinese Hamster Ovary (CHO) Cell Lines
11. Covance Opens New Clinical Development Offices in Chile, Peru and Expands Argentina Office
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/22/2016)... Washington, USA (PRWEB) , ... June 21, 2016 , ... ... and without cutting into the tissue — promise to enable both compact, wearable devices ... and from even deeper under the skin. , Recent work and visionary future directions ...
(Date:6/22/2016)...  Mesa Biotech Inc., a privately-held, molecular diagnostic ... specifically for point-of-care (POC) infectious disease diagnosis, today ... (SAB). Approved by the executive leadership team and ... advise on the development and commercialization of Mesa ... Steve Young , this world-class team brings ...
(Date:6/22/2016)... 22, 2016 On Tuesday, June 21, ... up 0.14%; the Dow Jones Industrial Average advanced 0.14% to ... up 0.27%. The gains were broad based as five out ... initiated coverage on the following equities: Minerva Neurosciences Inc. (NASDAQ: ... PTLA ), Trevena Inc. (NASDAQ: TRVN ), and ...
(Date:6/21/2016)... (PRWEB) , ... June 21, 2016 , ... Three young ... diseases and explore the depths of space with today’s announcement of the winners of ... Awards, given annually by the Blavatnik Family Foundation and administered by the New ...
Breaking Biology Technology:
(Date:4/15/2016)... 2016  A new partnership announced today will ... decisions in a fraction of the time it ... high-value life insurance policies to consumers without requiring ... Force Diagnostics, rapid testing (A1C, Cotinine and HIV) ... pressure, weight, pulse, BMI, and activity data) available ...
(Date:3/31/2016)... , March 31, 2016   ... ("LegacyXChange" or the "Company") LegacyXChange is excited ... of its soon to be launched online site for ... https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential shareholders a ... DNA technology to an industry that is notorious for ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):